Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI) announced the presentation of three new data sets from pivotal clinical studies at the 2022 TCT and VEINS conferences. The FLASH registry will showcase results from 800 patients treated with the FlowTriever system, focusing on safety and clinical outcomes, presented on September 18. The CLOUT registry results involving 500 patients will be shared on October 30-31, evaluating the ClotTriever system's effectiveness. A comparison of CLOUT data with ATTRACT outcomes will also be highlighted. These studies aim to refine the treatment standards for venous thromboembolism (VTE).

Positive

• Three major clinical studies to be presented at significant medical conferences.
• FLASH registry results are based on 800 patients, representing the largest device study for PE.
• CLOUT registry results involve 500 patients, noted as the largest study for DVT.
• Data presentation underlines Inari's commitment to establishing new treatment standards for VTE.

Negative

• None.

IRVINE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) and the 2022 VEINS (Venous Endovascular Interventional Strategies) conferences.

First, the in-hospital and 30-day results from the fully enrolled 800-patient US cohort of the FLASH registry will be presented at the TCT conference in Boston on September 18^th. FLASH is the largest prospective device study ever conducted in the field of PE. The study evaluates short and long-term clinical outcomes of patients treated with the FlowTriever system, including safety results, on-table hemodynamic improvements, and hospital resource utilization. The data will be presented by Dr. Catalin Toma (University of Pittsburgh Medical Center, Pittsburgh, PA, and global Principal Investigator (PI) for FLASH).

Second, the in-hospital and 30-day outcomes of the fully enrolled 500-patient, multi-center CLOUT registry will be presented at the VEINS meeting on October 30-31 in Las Vegas. CLOUT is the largest prospective mechanical thrombectomy study ever conducted in the field of DVT. The study evaluates the safety and effectiveness of the ClotTriever system including thrombus removal, hospital resource utilization, and long-term clinical results. The data will be presented by Dr. David Dexter (Sentara Vascular Specialists, Norfolk, VA and one of the national PIs for CLOUT).

Third, also to be presented at VEINS, is a propensity-matched comparison of patients treated in the CLOUT registry versus patients treated with pharmacomechanical thrombolysis from ATTRACT, an NIH-sponsored randomized controlled trial (RCT). Outcomes include procedural metrics, effectiveness of thrombus removal, and clinical results through 30 days. The data will be presented by Dr. Steven Abramowitz (MedStar Heath, Washington DC and PI for CLOUT).

“Having three studies presented as Late-Breaking Clinical Trials at major global conferences this fall is remarkable,” said Dr. Thomas Tu, Inari’s Chief Medical Officer. “This is a testament to both the need for high-quality evidence in the VTE space and the importance of these data. These studies, along with our two RCTs, DEFIANCE and PEERLESS, serve Inari’s mission to establish a new standard of care for VTE patients and further distance us from competition.”

About Inari Medical, Inc.

Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

What studies are being presented by Inari Medical at the TCT conference?

Inari Medical will present the in-hospital and 30-day results of the FLASH registry, which evaluates the FlowTriever system in 800 patients.

When will the CLOUT registry results be shared?

The CLOUT registry results will be presented at the VEINS meeting on October 30-31.

What is the focus of the FLASH registry study?

The FLASH registry focuses on short and long-term clinical outcomes, safety results, and hospital resource utilization for patients treated with the FlowTriever system.

How does the CLOUT registry compare to previous studies?

The CLOUT registry is the largest prospective mechanical thrombectomy study for DVT, focusing on the effectiveness of the ClotTriever system.

What is the significance of the studies presented by Inari Medical?

These studies represent high-quality evidence in the VTE treatment space and aim to establish new standards of care.